AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 312.9 USD | +1.81% |
|
+12.55% | +8.79% |
| 01:14pm | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
| 12:51pm | Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170 | MT |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 0 M€ | +3.25% | - | |
| 0.09% | 0 M€ | +2.51% | - | |
| 0.09% | 6 M€ | +3.89% | ||
| 0.06% | 26 M€ | +16.85% | - | |
| 0.05% | 0 M€ | +0.45% | - | |
| 0.05% | 0 M€ | +12.04% | - | |
| 0.04% | 0 M€ | +0.44% | - | |
| 0.04% | 6 M€ | -4.26% | - | |
| 0.04% | 0 M€ | +2.93% | - | |
| 0.02% | 0 M€ | +3.43% | - | |
| 11.86% | 0 M€ | +5.78% | - | |
| 15.31% | 0 M€ | +4.29% | - | |
| 211.11% | 0 M€ | +0.85% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
307.3
USD
Average target price
313.3
USD
Spread / Average Target
+1.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.79% | 165B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.45% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| -2.01% | 160B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.